Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options

Merck Sharp & Dohme LLC0 个研究点开始时间: 2006年9月15日最近更新: 2016年4月22日

适应症

试验速览

阶段: 不适用
状态: Approved For Marketing
发起方: Merck Sharp & Dohme LLC

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or intolerance to multiple antiretroviral regimens. Enrollment in this study is patient driven. Investigators are not proactively assigned. There is no target sample size and duration of the study is indefinite. For information on how to enroll in the study, see link below.

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 16 Years 至 —（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•HIV positive patients who have limited or no treatment options and have documented resistance

排除标准

•Patient has previously been on MK0518 therapy

研究者

发起方

Merck Sharp & Dohme LLC

申办方类型

Industry

责任方

Sponsor

相似试验

Approved For Marketing

3 期

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral DrugsHIV-1

NCT00354627Tibotec Pharmaceuticals, Ireland5,178

Approved For Marketing

不适用

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.HIV Infections

NCT00245739Tibotec Pharmaceuticals, Ireland

已完成

1 期

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected PatientsHIV InfectionHIV Infections

NCT01044654Sangamo Therapeutics19

已完成

2 期

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug CombinationHIV Infections

NCT00001132National Institute of Allergy and Infectious Diseases (NIAID)80

已完成

1 期

Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 TrialHIV/AIDS

NCT03391375EuroVacc Foundation49